The cancer therapeutic potential of Chk1 inhibitors: how mechanistic studies impact on clinical trial design

Differential regulation of p21waf1protein half-life by DNA damage and Nutlin-3 in p53 wild-type tumors and its therapeutic implications

(2012) Li-Ju Chang et al.   CANCER BIOLOGY & THERAPY

Human Nuclease/Helicase DNA2 Alleviates Replication Stress by Promoting DNA End Resection

(2012) G. Peng et al.   CANCER RESEARCH

Mre11-Dependent Degradation of Stalled DNA Replication Forks Is Prevented by BRCA2 and PARP1

(2012) S. Ying et al.   CANCER RESEARCH

The Intra-S Phase Checkpoint Targets Dna2 to Prevent Stalled Replication Forks from Reversing

(2012) Jiazhi Hu et al.   CELL

CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

(2012) M. I. Walton et al.   CLINICAL CANCER RESEARCH

Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias

(2012) J. E. Karp et al.   CLINICAL CANCER RESEARCH

SMARCAL1 catalyzes fork regression and Holliday junction migration to maintain genome stability during DNA replication

(2012) R. Betous et al.   GENES & DEVELOPMENT

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models

(2012) Cynthia X. Ma et al.   JOURNAL OF CLINICAL INVESTIGATION

Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: The molecular choreography

(2012) Larry H. Thompson   MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH

The Mre11 Nuclease Is Critical for the Sensitivity of Cells to Chk1 Inhibition

(2012) Ruth Thompson et al.   PLoS One

Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1

(2012) Marieke Aarts et al.   Cancer Discovery

Chk1 has an essential role in the survival of differentiated cortical neurons in the absence of DNA damage

(2011) Weizhen Ye et al.   APOPTOSIS

Claspin and Chk1 regulate replication fork stability by different mechanisms

(2011) Jennifer Scorah et al.   CELL CYCLE

Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase

(2011) Samuel McNeely et al.   CELL CYCLE

DNA end resection—Unraveling the tail

(2011) Eleni P. Mimitou et al.   DNA REPAIR

ATR–Chk1 signaling pathway and homologous recombinational repair protect cells from 5-fluorouracil cytotoxicity

(2011) Yoshihiko Fujinaka et al.   DNA REPAIR

Analysis of protein dynamics at active, stalled, and collapsed replication forks

(2011) B. M. Sirbu et al.   GENES & DEVELOPMENT

Preclinical Development of the Novel Chk1 Inhibitor SCH900776 in Combination with DNA-Damaging Agents and Antimetabolites

(2011) R. Montano et al.   MOLECULAR CANCER THERAPEUTICS

Cell cycle regulation of DNA double-strand break end resection by Cdk1-dependent Dna2 phosphorylation

(2011) Xuefeng Chen et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Single-Agent Inhibition of Chk1 Is Antiproliferative in Human Cancer Cell Lines In Vitro and Inhibits Tumor Xenograft Growth In Vivo

(2011) Kurtis D. Davies et al.   ONCOLOGY RESEARCH

Structure-Specific DNA Endonuclease Mus81/Eme1 Generates DNA Damage Caused by Chk1 Inactivation

(2011) Josep V. Forment et al.   PLoS One

Checkpoint Signaling, Base Excision Repair, and PARP Promote Survival of Colon Cancer Cells Treated with 5-Fluorodeoxyuridine but Not 5-Fluorouracil

(2011) Liyi Geng et al.   PLoS One

Anticancer therapy with checkpoint inhibitors: what, where and when?

(2011) Michelle D. Garrett et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Differences in the DNA replication of unicellular eukaryotes and metazoans: known unknowns

(2010) Alessia Errico et al.   EMBO REPORTS

The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106

(2010) M. I. Walton et al.   MOLECULAR CANCER THERAPEUTICS

Hydroxyurea-Stalled Replication Forks Become Progressively Inactivated and Require Two Different RAD51-Mediated Pathways for Restart and Repair

(2010) Eva Petermann et al.   MOLECULAR CELL

Rad51 protects nascent DNA from Mre11-dependent degradation and promotes continuous DNA synthesis

(2010) Yoshitami Hashimoto et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents

(2010) S Zenvirt et al.   ONCOGENE

Chk1 promotes replication fork progression by controlling replication initiation

(2010) E. Petermann et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The annealing helicase SMARCAL1 maintains genome integrity at stalled replication forks

(2009) C. E. Bansbach et al.   GENES & DEVELOPMENT

Human CtIP Mediates Cell Cycle Control of DNA End Resection and Double Strand Break Repair

(2009) Pablo Huertas et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The decision to enter mitosis: feedback and redundancy in the mitotic entry network

(2009) Arne Lindqvist et al.   JOURNAL OF CELL BIOLOGY

Cisplatin-Induced DNA Damage Activates Replication Checkpoint Signaling Components that Differentially Affect Tumor Cell Survival

(2009) J. M. Wagner et al.   MOLECULAR PHARMACOLOGY

Replication fork reversal and the maintenance of genome stability

(2009) J. Atkinson et al.   NUCLEIC ACIDS RESEARCH

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

(2008) A. Blasina et al.   MOLECULAR CANCER THERAPEUTICS

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

(2008) S. D. Zabludoff et al.   MOLECULAR CANCER THERAPEUTICS

Mrc1 and DNA Polymerase ɛ Function Together in Linking DNA Replication and the S Phase Checkpoint

(2008) Huiqiang Lou et al.   MOLECULAR CELL

The checkpoint kinases Chk1 and Chk2 regulate the functional associations between hBRCA2 and Rad51 in response to DNA damage

(2008) E M Bahassi et al.   ONCOGENE

Essential function of Chk1 can be uncoupled from DNA damage checkpoint and replication control

(2008) D. Wilsker et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

(2008) S. Shangary et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Replication forks, chromatin loops and dormant replication origins

(2008) J Julian Blow et al.   GENOME BIOLOGY

Cleavage of Stalled Forks by Fission Yeast Mus81/Eme1 in Absence of DNA Replication Checkpoint

(2007) Benoît Froget et al.   MOLECULAR BIOLOGY OF THE CELL